Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• Pyxis Oncology, Inc. has been given a consensus rating of "Moderate Buy" by six brokerages, with an average twelve-month price objective of $7.75.
• Institutional investors have increased their stakes in Pyxis, with Millennium Management boosting its stake by 53.8% during the fourth quarter.
• The company reported quarterly earnings of ($0.30) EPS, surpassing analysts' expectations and generating revenue of $2.82 million.

Pyxis Oncology, Inc. (NASDAQ:PYXS - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the six brokerages that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $7.75.

A number of equities analysts have recently commented on the company. Zacks Research raised Pyxis Oncology from a "strong sell" rating to a "hold" rating in a report on Monday, August 18th. HC Wainwright reissued a "buy" rating and set a $5.00 price objective on shares of Pyxis Oncology in a research note on Tuesday, August 19th. Guggenheim assumed coverage on Pyxis Oncology in a research note on Wednesday, September 3rd. They set a "buy" rating and a $5.00 price objective for the company. Finally, Wall Street Zen raised Pyxis Oncology from a "sell" rating to a "hold" rating in a research note on Sunday, August 24th.

Institutional Investors Weigh In On Pyxis Oncology

Large investors have recently added to or reduced their stakes in the business. Millennium Management LLC boosted its stake in Pyxis Oncology by 53.8% during the fourth quarter. Millennium Management LLC now owns 2,980,906 shares of the company's stock valued at $4,650,000 after buying an additional 1,043,228 shares during the period. Jane Street Group LLC lifted its stake in Pyxis Oncology by 36.6% during the fourth quarter. Jane Street Group LLC now owns 67,686 shares of the company's stock worth $106,000 after purchasing an additional 18,128 shares during the last quarter. ProShare Advisors LLC bought a new stake in Pyxis Oncology during the fourth quarter worth about $26,000. Ameriprise Financial Inc. bought a new stake in Pyxis Oncology during the fourth quarter worth about $35,000. Finally, Pier 88 Investment Partners LLC lifted its stake in Pyxis Oncology by 296.6% during the first quarter. Pier 88 Investment Partners LLC now owns 390,960 shares of the company's stock worth $383,000 after purchasing an additional 292,370 shares during the last quarter. Institutional investors own 39.09% of the company's stock.

Pyxis Oncology Price Performance

Pyxis Oncology stock opened at $2.19 on Wednesday. Pyxis Oncology has a one year low of $0.83 and a one year high of $5.39. The business has a fifty day moving average price of $1.42 and a 200-day moving average price of $1.22. The firm has a market capitalization of $135.82 million, a P/E ratio of -1.37 and a beta of 1.14.

Pyxis Oncology (NASDAQ:PYXS - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.30) EPS for the quarter, topping analysts' consensus estimates of ($0.36) by $0.06. The company had revenue of $2.82 million during the quarter. Sell-side analysts expect that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.